Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm

BMC Cancer

Table 3 Association of α-internexin protein expression with clinicopathological variables

Characteristics	N	Reduced/loss of expression (%)	χ2 value	P value
GEP-NENs (n = 286)
Functional status			6.213	0.013
Nonfunctional	234	179(76.5)
Functional	52	31(59.6)
Tumor location			2.356	0.308
Gastrointestinal tract	162	124(76.5)	2.340^d	0.126^d
Rectum	60	32(53.3)	43.470^e	< 0.001^e
Stomach	43	42(97.7)
Duodenum	21	17(81.0)
Esophagus	18	18(100)
Jejunum/ileum	9	9(100)
Appendix	6	2(33.3)
Colon	5	4(80.0)
Pancreas	93	63(67.7)
Other	31	23(74.2)
Tumor grade^a			49.934	< 0.001
G1	120	69(57.5)
G2	57	36(63.2)
G3	101	99(98.0)
Tumor type^a			46.807	< 0.001
NET	180	108(60.0)
NEC + MANEC	98	96(98.0)
Tumor stage			28.106	< 0.001
I + II	140	83(59.3)
III + IV	146	127(87.0)
GI-NENs (n = 162)
Tumor grade^b			41.938	< 0.001
G1	60	31(51.7)
G2	21	14(66.7)
G3	75	74(98.7)
Tumor type^b			40.004	< 0.001
NET	81	45(55.6)
NEC + MANEC	75	74(98.7)
Tumor stage			25.786	< 0.001
I + II	74	43(58.1)
III + IV	88	81(92.0)
pNENs (n = 93)
Tumor grade^c			2.929	0.231
G1	54	34(63.0)
G2	27	19(70.4)
G3	10	9(90.0)
Tumor type^c			1.080	0.299
NET	84	56(66.7)
NEC + MANEC	7	6(85.7)
Tumor stage			4.638	0.031
I + II	60	36(60.0)
III + IV	33	27(81.8)

^a 278 cases both for tumor grade and tumor type; ^b 156 cases both for tumor grade and tumor type; ^c 91cases both for tumor grade and tumor type; ^d The χ2 and P value were computed by the contrast between gastrointestinal tract and pancreas; ^e The χ2 and P value were computed by the contrast among different sites of gastrointestinal tract
GEP-NEN: Gastroenteropancreatic neuroendocrine neoplasm; NET: Neuroendocrine tumor; NEC: Neuroendocrine carcinoma; MANEC: Mixed adenoneuroendocrine carcinoma; GI-NEN: Gastrointestinal neuroendocrine neoplasm; pNEN: Pancreatic neuroendocrine neoplasm

ISSN: 1471-2407